C-myc, a proto-oncogene, the activation of which is associated with cancer formation, has been found to be essential for normal functioning of the immune system, according to a study published in ...

c-Myc is helix–loop–helix–leucine zipper (HLH–ZIP) oncoprotein that is frequently deregulated in human cancers. In order to bind DNA, regulate target gene expression, and function in a ...

The c-myc gene is commonly activated in a variety of human tumors. As a new report in the October 1 issue of Genes & Development shows, scientists are gaining a better understanding as to why. Dr ...

Summary Deregulated expression of c-MYC occurs in a broad range of human cancers and is often associated with poor prognosis, indicating a key role for this oncogene in tumour progression. However ...

Researchers have determined the mechanism used by c-Myc to increase the expression of all active genes in cancer cells. Elevated levels of c-Myc are linked to increased rates of metastasis ...

Secondly, c-MYC represses an inhibitor of SIRT1, so releasing a further brake on its function. Finally, SIRT1 itself potentiates these effects by reducing the rate of degradation of c-MYC.

Myc is one of the most frequently mutated, widely studied, and overexpressed genes implicated in cancer.. Most mutations in the myc gene lead to its constitutive expression. The myc gene codes for ...

The gene MYC is the most overexpressed oncogene in human cancers. Scientists had long believed that when MYC binds to a target gene, it turns that gene on, or activates it.

Reducing Myc gene increases lifespan of mice by 15% on average April 7, 2017 January 22, 2015 by Brian Wang A team of scientists based at Brown University has found that reducing expression of a ...

Whitehead Institute researchers have determined the mechanism used by c-Myc to increase the expression of all active genes in cancer cells. Elevated levels of c-Myc are linked to increased rates ...

Scientists have long known that in tumor cells, elevated levels of MYC’s protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and ...

Scientists have long known that in tumor cells, elevated levels of MYC’s protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and ...